This bill, titled the "Protecting Equal Access to Thyroid Act of 2026" (PEAT Act of 2026), changes one sentence in the Public Health Service Act (section 351(i)(1)). It adds a rule that a biologic may not be treated as a biological product based only on the presence of a protein that is a clinically inactive component. The bill also makes a small punctuation correction in the same section. The bill was introduced in the House on April 30, 2026, and referred to the House Committee on Energy and Commerce. Sponsors listed include Michael Rulli, Diana Harshbarger, and several other Representatives.
If this bill becomes law, the legal text in section 351(i)(1) of the Public Health Service Act would say that a biologic cannot be classified as a biological product solely because it contains a clinically inactive protein. This is a change to how that specific part of the statute would read. How agencies, manufacturers, or others would act in response is not described in the provided text.
No publicly available information on costs or budgetary effects is included in the provided bill text or metadata.
No publicly available information on proponents' stated reasons or arguments is included in the provided bill text or metadata.
No publicly available information on opponents' stated reasons or arguments is included in the provided bill text or metadata.